Indacaterol - Novartis
Alternative Names: Arcapta Neohaler; Hirobriz Breezhaler; Indacaterol maleate; Onbrez Breezhaler; Onbrez Inhalation Capsules; Onbrize Breezhaler; Oslif Breezhaler; QAB 149Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Novartis
- Class Antiasthmatics; Bronchodilators; Indans; Quinolones; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic obstructive pulmonary disease
- Phase III Asthma
Most Recent Events
- 27 Apr 2022 No development reported - Phase-II for Asthma (In adolescents, In the elderly, In adults) in Germany, Belgium, Slovakia (Inhalation) (EudraCT-2004-004095-37)
- 27 Apr 2022 No development reported - Phase-II for Asthma (In children) in Turkey, South Africa, Russia, Philippines, Guatemala, Croatia, Colombia (Inhalation) (NCT02892019)
- 27 Apr 2022 No development reported - Phase-II for Chronic obstructive pulmonary disease (In adolescents, In the elderly, In adults) in Belgium, Germany, Slovakia (Inhalation) (EudraCT-2004-004095-37)